# Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

> **NCT00047190** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Essential Thrombocythemia
- Polycythemia Vera
- Primary Myelofibrosis

## Interventions

- **DRUG:** tipifarnib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00047190
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2007-04
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047190, "Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00047190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*